A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer
- 1 November 2002
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 24 (11) , 1902-1914
- https://doi.org/10.1016/s0149-2918(02)80087-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCERJournal of Urology, 2000
- FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHMJournal of Urology, 2000
- Sustained suppression of pituitary‐gonadal axis with an injectable, in situ forming implant of leuprolide acetateJournal of Pharmaceutical Sciences, 2000
- Development of GnRH Antagonists for Prostate Cancer: New Approaches to TreatmentThe Oncologist, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate CancerUrologia Internationalis, 1998
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- Efficacy and Safety of Leuprorelin Acetate Depot for Prostate CancerUrologia Internationalis, 1996
- LeuprorelinDrugs, 1994
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960